Filing Analysis
Wellgistics Health received an extension from Nasdaq to remedy a deficiency in stockholders' equity, which was negative $(12,447,801) as of December 31, 2025. While the company has regained compliance with the minimum bid price requirement, it must now prove it meets the $2.5 million equity threshold by October 12, 2026.
🚩 Red Flags
- Severe negative stockholders' equity of over $12 million for a micro-cap company.
- Dependence on speculative future transactions (merger and acquisitions) to avoid delisting.
- Multiple 8-K items (3.01 and 8.01) indicating ongoing volatility in listing status.
📋 Key Facts
- Stockholders' equity as of December 31, 2025, was negative $(12,447,801), failing Nasdaq Rule 5550(b)(1) which requires at least $2,500,000.
- Nasdaq granted an extension until October 12, 2026, to regain compliance with the equity requirement.
- The company plans to remedy the deficiency through a combination with DataVault AI (creating 'DelivMeds AI') and the acquisition of a patent portfolio and stake in Tollo Health.
- Management estimates post-transaction stockholders' equity of approximately $40 million and combined asset value of $4 billion.
- The company successfully regained compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)) as of June 9, 2026.
Wellgistics Health, Inc. filed Amendment No. 2 to a previous 8-K to replace and refile Exhibit 4.3, which is the Form of Placement Agent Warrant. This is a technical correction to a prior filing and does not report new material events.
📋 Key Facts
- The filing is an Amendment No. 2 to a Current Report on Form 8-K originally filed on May 29, 2026.
- The primary purpose is to replace and refile Exhibit 4.3 (Form of Placement Agent Warrant).
- The filing date is June 3, 2026, regarding events that occurred on May 27, 2026.
Wellgistics Health, Inc. filed an 8-K/A amendment to provide exhibits that were omitted from a previous filing. The omitted documents include a Form of Placement Agent Warrant and a press release dated May 27, 2026, indicating a recent securities offering.
🚩 Red Flags
- Administrative oversight: The company inadvertently omitted material exhibits (Warrants and Press Release) from its original 8-K filing, suggesting poor internal controls over SEC reporting.
📋 Key Facts
- The filing is an Amendment No. 1 to a Current Report on Form 8-K originally filed on May 29, 2026.
- The amendment was filed on June 2, 2026.
- The primary purpose was to include Exhibit 4.3 (Form of Placement Agent Warrant) and Exhibit 99.1 (Press Release from May 27, 2026).
- The company is registered on the Nasdaq Capital Market under the ticker WGRX.
Wellgistics Health, Inc. entered into a Securities Purchase Agreement on May 27, 2026, to issue convertible promissory notes with an aggregate principal amount of $21,132,812.50. The offering includes a significant original issue discount (OID) and warrants, with proceeds partially used to repay a $1.77 million debt to Marco Capital, Inc.
🚩 Red Flags
- Significant 20% Original Issue Discount (OID) indicates high cost of capital and potential desperation for liquidity
- Complex 'death spiral' characteristics: conversion price is tied to 100% of the closing price, allowing for significant dilution if the stock price drops
- Liquidated damages provision in the Registration Rights Agreement (1.5% of subscription amount) creates a financial penalty for SEC delays
- The use of proceeds to pay off existing debt (Marco Capital) rather than purely for growth/working capital
📋 Key Facts
- Aggregate principal amount of Notes: $21,132,812.50
- Aggregate cash proceeds received: $16,906,250 (reflecting a 20% original issue discount)
- Notes mature in 12 months and bear 0% interest
- Notes are convertible into Common Stock at the lesser of $6.00 or 100% of the prior day's closing price (floor of $1.00)
- Automatic conversion into Series A Convertible Preferred Stock occurs upon the 'Mandatory Conversion Date'
- Series A Preferred Stock accrues 10% dividends after six months
- PIPE Warrants exercise price: $7.50; Placement Agent Warrants exercise price: $6.25
- Used proceeds to repay approximately $1.77 million in obligations to Marco Capital, Inc.
Wellgistics Health, Inc. issued a letter to its shareholders on May 21, 2026, providing a strategy overview and business update.
📋 Key Facts
- The filing was made under Item 8.01 (Other Events) on May 21, 2026.
- The company attached a Letter to Shareholders as Exhibit 99.1.
- The letter outlines the company's current strategy overview and business update.
Wellgistics Health, Inc. (WGRX) filed a multi-item 8-K disclosing a 1-for-50 reverse stock split effective May 26, 2026 to regain Nasdaq compliance, alongside a Fully Binding Letter of Intent for a transformative multi-party acquisition that would result in existing public shareholders retaining only ~10.4% of the combined company. The filing also discloses an amendment to a promissory note with a 20% OID, appointment of an Interim Co-CEO with significant related-party ties, and a proposed corporate rename to DelivMeds AI, Inc.
🚩 Red Flags
- 1-for-50 reverse stock split is an extreme ratio, signaling severe share price deterioration and Nasdaq non-compliance (Rule 5550(a)(2) bid price deficiency)
- Existing public shareholders face ~89.6% dilution upon conversion of Acquisition Preferred — near-total economic displacement
- Newly appointed Interim Co-CEO (Commissiong) has direct financial interest in the transaction through Fortitude Advisors (~5.0% of post-conversion common stock) and is CEO of an acquisition target (Tollo Health) — severe related-party conflict
- Promissory note carries a 20% original issue discount, indicating predatory/distressed financing terms; aggregate OID burden = $300,000 on $1.5M principal
- Six separate 8-K items filed simultaneously, indicating multiple concurrent material events under financial and operational stress
- Company explicitly states it 'cannot provide assurance' the reverse split will achieve desired effects or maintain Nasdaq listing
- $4.0 billion combined valuation claim is highly speculative for a micro-cap with no definitive agreements, no completed due diligence, and no fairness opinion yet issued
- Binding exclusivity provisions lock the company into negotiations, limiting strategic alternatives during a vulnerable period
- Corporate name change to DelivMeds AI, Inc. suggests pivot away from core pharmacy/health operations — strategic direction uncertainty
📋 Key Facts
- 1-for-50 reverse stock split approved by board (April 2, 2026) and majority stockholders; effective 12:01 a.m. ET on May 26, 2026 under existing symbol WGRX
- Reverse split explicitly triggered by Nasdaq non-compliance with Listing Rule 5550(a)(2) — bid price below $1.00
- Binding LOI dated May 20, 2026 with EOS Technology Holdings, Scilex Holding Company (SCLX), Datavault AI, HealthBridge Advisors, and Fortitude Advisors for multi-party asset acquisition
- Transaction would issue 'Acquisition Preferred' convertible into ~89.6% of common stock to transaction counterparties; existing public shareholders retain only ~10.4%
- Proposed combined entity valuation of $4.0 billion per term sheet, subject to fairness opinion
- Amendment No. 1 to Note Purchase Agreement with Robert Forster (May 19, 2026): additional $200,000 funded, aggregate cash raised to $1,200,000, note principal increased to $1,500,000 with 20% original issue discount
- Gerald Commissiong appointed Interim Co-CEO effective May 20, 2026; he is simultaneously Managing Partner of Fortitude Advisors (a Term Sheet counterparty expected to receive ~5.0% of common stock) and CEO of Tollo Health (target acquisition)
- Term Sheet contemplates corporate name change to DelivMeds AI, Inc., two new management members, and four new board designees
- At-the-market funding facility filing required within 14 days of Term Sheet; target concurrent minimum investment of $2.0 million from Dawson James-associated investors
- No assurance provided that Nasdaq listing will be maintained or that the proposed transaction will be consummated
Wellgistics Health, Inc. filed a Form 8-K on May 19, 2026, to announce its financial results for the quarter ended March 31, 2026. The filing incorporates Item 2.02 and Item 7.01, referencing an attached press release.
📋 Key Facts
- Wellgistics Health, Inc. reported its financial results for the quarter ended March 31, 2026.
- The press release was furnished as Exhibit 99.1 under Items 2.02 and 7.01.
- The filing was signed by CEO Prashant Patel on May 19, 2026.
Wellgistics Health, Inc. announced that it will report its first quarter 2026 financial results on Tuesday, May 19, 2026, after the market closes.
📋 Key Facts
- Wellgistics Health announced on May 15, 2026, that it will release its Q1 2026 financial results on May 19, 2026, after market close.
- The announcement was made via a press release furnished as Exhibit 99.1.
- The filing was submitted under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits).
Wellgistics Health, Inc. has withdrawn its Preliminary Proxy Statement filed on May 14, 2026, regarding a special meeting of stockholders. The company stated the withdrawal is necessary as they continue to evaluate potential strategic transactions.
🚩 Red Flags
- Abrupt withdrawal of proxy materials shortly after filing suggests internal indecision or a sudden change in corporate direction.
- Lack of specificity regarding the 'strategic transactions' creates uncertainty for investors.
📋 Key Facts
- The withdrawal request was filed on May 18, 2026, only four days after the initial proxy filing.
- The proxy materials related to a special meeting of stockholders.
- No definitive proxy materials were distributed or mailed to stockholders prior to the withdrawal.
- The company cited the evaluation of 'potential strategic transactions' as the primary reason for the pivot.
- Revised proxy materials may be filed at a later date depending on the outcome of strategic evaluations.
Wellgistics Health, Inc. entered into a forbearance agreement with Marco Capital, Inc. regarding approximately $1.77 million in outstanding debt. The agreement requires bi-weekly payments and imposes a high interest rate while providing only a short-term reprieve through June 15, 2026.
🚩 Red Flags
- Existence of a forbearance agreement indicates a prior default or inability to meet original loan terms.
- Very high interest rate (SOFR + 11.5%) typical of distressed debt.
- Short forbearance window (approx. 6 weeks) suggests immediate liquidity crisis.
- Personal guaranties from management (Prashant Patel and Eric Sherb) increase risk profile.
- Mandatory sweep of future financing proceeds limits the company's ability to use new capital for operations.
📋 Key Facts
- Acknowledged $1.77 million in outstanding debt under a November 2024 Loan and Security Agreement.
- Forbearance period is extremely short, expiring on June 15, 2026.
- Interest rate set at Term SOFR plus 11.5% per annum starting May 5, 2026.
- Required bi-weekly payments of $50,000 beginning May 5, 2026.
- Net proceeds from future financing transactions must be partially applied to the debt repayment.
- Management members Prashant Patel and Eric Sherb reaffirmed personal guaranties.
Wellgistics Health, Inc. filed an amendment (8-K/A) to a previous report to correct the reporting date to February 9, 2026, and to restate the entry into an Amended Settlement Agreement with Silverback Capital Corporation.
🚩 Red Flags
- The company is filing an amendment to correct the date and restate a material agreement, which may indicate poor internal controls over financial reporting or filing accuracy.
📋 Key Facts
- The filing is an Amendment No. 1 to a Current Report originally filed on February 13, 2026.
- The report corrects the Date of Report to February 9, 2026.
- The company entered into an Amended Settlement Agreement with Silverback Capital Corporation on February 9, 2026.
- The filing specifically restates Item 1.01 to clarify the timing and nature of the material definitive agreement.
Wellgistics Health filed an amended 8-K disclosing a Nasdaq delisting notice due to failure to meet the minimum stockholders' equity requirement of $2.5 million. Simultaneously, the company entered into a collaboration agreement to form a joint venture (Healthstar) with Kare Rx Hub and others, paying up to $2 million in common stock for assets.
🚩 Red Flags
- Severe negative stockholders' equity of approximately -$12.45 million.
- Delisting notice from Nasdaq Capital Market.
- Multiple 8-K items in a single filing (1.01, 3.01, 3.02, 7.01), indicating high volatility/activity.
- Issuance of unregistered shares to resolve asset acquisition while facing insolvency/delisting risks.
📋 Key Facts
- Received Nasdaq Notification Letter on April 13, 2026, regarding non-compliance with Listing Rule 5550(b)(1).
- Company's stockholders' equity was reported as $(12,447,801) as of December 31, 2025, far below the $2.5 million requirement.
- Deadline to submit a compliance plan to Nasdaq is May 28, 2026.
- Entered into a Collaboration Agreement on April 13, 2026, to form 'Healthstar' (51% owned by Wellgistics, 49% by Kare Hub).
- Agreed to pay Kare Pharmtech $2,000,000 in unregistered common stock for transferred assets.
- Initial issuance of 1,500,000 shares at closing, with potential additional shares by April 1, 2027, to reach the $2M valuation.
Wellgistics Health (WGRX) entered into a Collaboration Agreement with Kare Rx Hub to form a joint venture, Healthstar Technologies, LLC, in which WGRX will hold a 51% interest. The company will acquire intellectual property assets for $2 million, payable in common stock, with a share reconciliation provision scheduled for April 2027.
🚩 Red Flags
- Potential for significant future dilution due to the price-based share reconciliation clause on April 1, 2027, which acts as a floorless reset.
- Discrepancy in dates: Agreement signed April 13, 2026, but closing mentioned as occurring on or about April 10, 2026.
📋 Key Facts
- WGRX acquires 51% membership interest in newly formed Healthstar Technologies, LLC.
- Total consideration is $2,000,000 in unregistered common stock.
- Initial issuance of 1,500,000 shares at closing.
- A 'Reconciliation Date' of April 1, 2027, allows for additional share issuance to ensure the $2M value is met based on a 2-day VWAP.
- Shares are subject to a 12-month lock-up period.
Wellgistics Health, Inc. terminated a Settlement Agreement with Silverback Capital Inc. that facilitated debt-for-equity swaps under Section 3(a)(10). The company issued 6,866,000 shares prior to termination and is ending the arrangement to prevent further dilution and pursue alternative financing.
🚩 Red Flags
- Reliance on Section 3(a)(10) share issuances, which are often highly dilutive and used by companies in financial distress.
- Significant share issuance (6.86M shares) occurred in a very short window (approximately 2 months).
- Sudden termination of a material financing structure suggests a shift in strategy or potential friction with the settlement terms.
📋 Key Facts
- Termination notice delivered to Silverback Capital Inc. on April 3, 2026.
- The original Settlement Agreement and Stipulation was dated January 28, 2026.
- A total of 6,866,000 shares of common stock were issued under the agreement prior to its termination.
- The agreement utilized Section 3(a)(10) of the Securities Act of 1933 for share issuance.
- Silverback Capital Inc. has been requested to return all rights and interests in unpaid claims to the original creditors.
Wellgistics Health, Inc. entered into a Note Purchase Agreement to raise $1,000,000 in cash through the issuance of $1,250,000 in promissory notes, representing a 20% original issue discount. The notes mature in 12 months or upon the closing of a qualified financing and carry restrictive covenants against additional debt.
🚩 Red Flags
- High cost of capital: 20% original issue discount for a 12-month term.
- Restrictive covenants: The company cannot incur additional debt or liens, which may severely limit operational flexibility if cash needs exceed the $1M raised.
- Potential for dilution: Investors have participation rights in future offerings for up to 100% of their principal.
📋 Key Facts
- Note Purchase Agreement dated April 1, 2026, for up to $1,250,000 in aggregate principal.
- Investors paid an aggregate purchase price of $1,000,000, reflecting a 20% original issue discount (OID).
- Notes carry a 0% interest rate, increasing to 15% only in the event of default.
- Maturity is set for the 12-month anniversary of issuance or the closing of the next 'Qualified Financing'.
- Investors receive a right to participate in future offerings up to 100% of their note principal for at least one year.
- The company is prohibited from incurring new debt or granting liens while the notes are outstanding.
Wellgistics Health, Inc. entered into a 36-month Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC to distribute the 'KARE Verify' benefits verification product. The agreement provides for a 50/50 net revenue split between the two companies.
📋 Key Facts
- Agreement signed on March 6, 2026, with Kare PharmTech LLC.
- Product involved is 'KARE Verify,' which provides benefits and eligibility verification services.
- Wellgistics will utilize its pharmacy, manufacturer, and distribution channels, including telemedicine platforms, for marketing.
- Net revenue will be shared equally (50% each) between the Company and PharmTech.
- The agreement has a standard term of 36 months unless terminated earlier.
Wellgistics Health, Inc. issued a press release on March 9, 2026, regarding the company's projects, potential financial performance, and growth opportunities. The information was furnished under Item 7.01 and is not considered filed for regulatory liability purposes.
📋 Key Facts
- Press release issued and furnished on March 9, 2026
- Company is classified as an emerging growth company
- Common stock is listed on The Nasdaq Capital Market under the symbol WGRX
- Reference made to a Registration Statement on Form S-1 that became effective on September 25, 2025